Conference Coverage

‘Organoid technology’ poised to transform cancer care


 

REPORTING FROM THE ACS CLINICAL CONGRESS

– Imagine being able to biopsy a tumor and grow it in a lab.

The implications are nearly endless. To start, chemotherapy and radiation options could be screened in vitro, much like culture and sensitivity testing of bacteria, to find a patient’s best option. Tumor cultures could be banked for mass screening of new cytotoxic candidates.

It’s already beginning to happen in a few research labs around the world, and it might foretell a breakthrough in cancer treatment.

After decades of failure, the trick to growing tumor cells in culture has finally been figured out. When stem cells are fished out of healthy tissue – from the crypts of the gastrointestinal lining, for instance – and put into a three-dimensional matrix culture with growth factors, they grow into little replications of the organs they came from, called “organoids;” when stem cells are pulled from cancers, they replicate the primary tumor, growing into “tumoroids” ready to be tested against cytotoxic drugs and radiation.

Philip B. Paty, MD, FACS, a colorectal surgeon and organoid researcher at Memorial Sloan Kettering Cancer Center, New York, said he is certain that the person who led the team that figured out the right culture condition – Hans Clevers, MD, PhD, a molecular genetics professor at the University of Utrecht (the Netherlands) – is destined for a Nobel Prize.

Dr. Paty took a few minutes at the annual clinical congress of the American College of Surgeons to explain in an interview why, and what ‘organoid technology’ will likely mean for cancer treatment in a few years.

“The ability to grow and sustain cancer means that we now can start doing real science on human tissues. We could never do this before. We’ve been treating cancer without being able to grow tumors and study them.” The breakthrough opens the door to “clinical trials in a dish,” and will likely take personalized cancer treatment to a new level, he said.

“It remains to be proven that “organoid technology “can change outcomes for patients, but those studies are likely coming,” said Dr. Paty, who investigates tumoroid response to radiation in his own lab work.

Recommended Reading

Study eyes liver transplantation after Region 5 UNOS downstaging
MDedge Hematology and Oncology
PREOPANC-1: Early findings suggest benefit with preop chemo in pancreatic cancer
MDedge Hematology and Oncology
Breast cancer patients don’t get the financial counseling they want from their clinicians
MDedge Hematology and Oncology
Neoadjuvant-treated N2 rectal cancer linked to PCR failure
MDedge Hematology and Oncology
More frequent CT surveillance in NSCLC doesn’t improve survival
MDedge Hematology and Oncology
Opioid use cut nearly 50% for urologic oncology surgery patients
MDedge Hematology and Oncology
Cervical cancer survival higher with open surgery in LACC trial
MDedge Hematology and Oncology
'Liver first' for select stage IV colon cancer gaining traction
MDedge Hematology and Oncology
Nipple-sparing mastectomy safe in older patients
MDedge Hematology and Oncology
SRS beats surgery in early control of brain mets, advantage fades with time
MDedge Hematology and Oncology